Clinical Trial Update: Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating enzalutamide with or without radium-223 dichloride in metastatic castration-resistant prostate cancer is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)
• Xtandi (enzalutamide)

Snippet

Sponsor: University of Southern California | Conditions: Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Status: ACTIVE_NOT_RECRUITING